Browsing category:

Hormonal Agent


As the leading cause of blindness in the United States Diabetic Macular Edema {DME} is a serious concern for the growing aging population, affecting roughly one million Americans. The recent announcement from pSivida Corp. regarding the marketing authorization in the EU of their DME treatment Fluocinolone is hopeful for U.S. supporters of this formidable drug.[…]

Read More

The biopharmaceutical company Rockwell Medical is anxiously awaiting approval from the FDA for its injectable Vitamin D drug, Calcitriol CAS# 32222-06-3. This promising new indication approval was submitted in April of 2013, with the goal of better managing hypocalcemia in patients who experience chronic renal dialysis. As an active injectable treatment known as the brand[…]

Read More

In mid-November 2013 the FDA announced their recommendation for the approval of Tasimelteon for the treatment of non-24-disorder. This rare condition, which primarily affects the blind, occurs when the body’s biological clock does not work properly. Patients who are blind and experience this frustrating type of insomnia can now find relief, as Tasimelteon effectively resets[…]

Read More

Exciting results were revealed in Mid-March of 2013 when the REMINDER trial touted the success of Eplerenone for treating acute ST-Segment Elevation Myocardial Infarction, also known as STEMI. The results from this study were presented at the 62nd Annual Scientific Session of the American College of Cardiology, by Pfizer, who markets Inspra which is the[…]

Read More

Ethinyl Estradiol CAS# 57-63-6 Ethinyl Estradiol, CAS number 57-63-6 and Norgestimate, CAS number 35189-28-7, are both integral components in the blockbuster birth control pill Ortho Tri-Cyclen Lo. Mylan and Janssen, who market Ortho Tri-Cyclen Lo, reported an astounding 425.5 million dollars in sales for the United States for the 2012 year. With the patent for[…]

Read More

Testosterone CAS# 58-22-0, made the pharmaceutical headlines mid June 2013 when study findings were announced touting¬†testosterone for perceived pain relief. Data presented on June 17, 2013, at the Endocrine Society’s 95th Annual Meeting offered positive results regarding the use of testosterone to improve pain tolerance. The study funded by Abbott Pharmaceuticals, involved 84 men who[…]

Read More

On October 3, 2013 the FDA approved the new medication Duavee, comprised of Bazedoxifene and conjugated estrogens (Premarin) to treat hot flashes in postmenopausal women. The unique ability of this novel treatment to curtail hot flashes and help prevent osteoporosis is encouraging for gynecologists and their female patients who are experiencing post-menopause. The combination of[…]

Read More

Is Testosterone a potential preventative treatment for type 2 diabetes? Researchers at the University of Adelaide in Australia are hopeful that their latest research will be the kick-start for trials of testosterone as a preventative for this encompassing from of diabetes. Results from early stages of this current study, which were discussed at the 10th[…]

Read More

Drospirenone is a key ingredient alongside Estradiol in the birth control pill Angeliq. The patent for Angeliq expires on August 11, 2017, making way for the development of generic options of this versatile hormone regulating medication. Developed as a birth control medication, used to prevent pregnancy, Angeliq works by preventing ovulation and causing changes in[…]

Read More